AN2 Therapeutics Inc. ( ANTX ) shares were down during Wednesday’s premarket session in a volatile session. At the open, the stock recovered the losses.

AN2 Therapeutics’ $40 Million Financing

The company surged over 90% on Tuesday following a recent announcement regarding a $40 million private placement financing.

The financing includes the sale of around 8.2 million shares at $2.85 each, along with pre-funded warrants for up to 5.8 million additional shares at a nearly identical purchase price.

Focuses On Lead Drug Development For Rare Blood Disorder

Last week, AN2 Therapeutics ( ANTX ) announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV).

PV is a blood cancer characterized by overproduction of red blood cells in the bone marrow.

The company is currently proceeding through the regulatory clearance process and anticipates initiating the Phase 2 trial in the third quarter of 2026.

AN2 Therapeutics ( ANTX ) expects to provide periodic public data updates as early as the fourth quarter of 2026 and throughout 2027, subject to regulatory clearance and enrollment progress.

ANTX Price Action: AN2 Therapeutics ( ANTX ) shares were up 3.48% at $5.65 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock